drugset / Trial / NCT05919381

Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.

NCT05919381

Phase 3 Unknown 752 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of the combination of Gentuximab Injection and Paclitaxel Injection in patients with advanced gastric or gastroesophageal junction adenocarcinoma after first-line treatment failure compared with Placebo and Paclitaxel Injection.

Timeline

Start
2022-05-30
Primary completion
2024-12
Completion
2025-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gentuximab Monoclonal antibody 8 mg/kg Intravenous